Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben Goldacre

Showing results (61-70 of 264) with videos related to

Pageof 27
Sort By:
Health Policy (Amsterdam, Netherlands)|February 28, 2024
Barriers and best practices to improving clinical trials transparency at UK public research institutions: A qualitative interview studyNicholas J DeVito, Jessica Morley, Ben Goldacre
BMJ (Clinical Research Ed.)|March 9, 2017
Authors' reply to BealesBen Goldacre, Samuel Whittle, Edzard Ernst, et al.
The Journal of Antimicrobial Chemotherapy|January 29, 2019
Impact of Chief Medical Officer activity on prescribing of antibiotics in England: an interrupted time series analysisAlex J Walker, Helen J Curtis, Ben Goldacre
Lancet (London, England)|August 2, 2016
Outcomes in the trial registry should match those in the protocolHenry Drysdale, Eirion Slade, Ben Goldacre, et al.
Evidence-Based Dentistry|October 27, 2018
Too few trials or too few reported trials?Andrés Viteri-García, Nicholas J DeVito, Ben Goldacre
Evaluation & the Health Professions|November 28, 2009
Interpretive bias in acupuncture research?: A case studyNeil E O'Connell, Benedict M Wand, Ben Goldacre
British Journal of Cancer|April 24, 2018
Impact of NICE guidance on tamoxifen prescribing in England 2011-2017: an interrupted time series analysisHelen J Curtis, Alex J Walker, Ben Goldacre
BMJ (Clinical Research Ed.)|July 26, 2018
Prescribing biosimilarsJeffrey K Aronson, Ben Goldacre, Robin E Ferner
BMJ (Clinical Research Ed.)|September 11, 2016
Problems with ethical approval and how to fix them: lessons from three trials in rheumatoid arthritisJonathan Mendel, Ben Goldacre, Edzard Ernst, et al.
BMJ (Clinical Research Ed.)|November 23, 2019
Why researchers should share their analytic codeBen Goldacre, Caroline E Morton, Nicholas J DeVito
Pageof 27

Showing results (61-70 of 264) with videos related to

Sort By:
Pageof 27
Health Policy (Amsterdam, Netherlands)|February 28, 2024
Barriers and best practices to improving clinical trials transparency at UK public research institutions: A qualitative interview studyNicholas J DeVito, Jessica Morley, Ben Goldacre
BMJ (Clinical Research Ed.)|March 9, 2017
Authors' reply to BealesBen Goldacre, Samuel Whittle, Edzard Ernst, et al.
The Journal of Antimicrobial Chemotherapy|January 29, 2019
Impact of Chief Medical Officer activity on prescribing of antibiotics in England: an interrupted time series analysisAlex J Walker, Helen J Curtis, Ben Goldacre
Lancet (London, England)|August 2, 2016
Outcomes in the trial registry should match those in the protocolHenry Drysdale, Eirion Slade, Ben Goldacre, et al.
Evidence-Based Dentistry|October 27, 2018
Too few trials or too few reported trials?Andrés Viteri-García, Nicholas J DeVito, Ben Goldacre
Evaluation & the Health Professions|November 28, 2009
Interpretive bias in acupuncture research?: A case studyNeil E O'Connell, Benedict M Wand, Ben Goldacre
British Journal of Cancer|April 24, 2018
Impact of NICE guidance on tamoxifen prescribing in England 2011-2017: an interrupted time series analysisHelen J Curtis, Alex J Walker, Ben Goldacre
BMJ (Clinical Research Ed.)|July 26, 2018
Prescribing biosimilarsJeffrey K Aronson, Ben Goldacre, Robin E Ferner
BMJ (Clinical Research Ed.)|September 11, 2016
Problems with ethical approval and how to fix them: lessons from three trials in rheumatoid arthritisJonathan Mendel, Ben Goldacre, Edzard Ernst, et al.
BMJ (Clinical Research Ed.)|November 23, 2019
Why researchers should share their analytic codeBen Goldacre, Caroline E Morton, Nicholas J DeVito
Pageof 27